April 1, 2026: Patient Form Temporary Outage Notice – Patient forms will be unavailable tonight from 9:00 PM – 5:00 AM EST due to scheduled maintenance. Access will be restored on April 2, 2026, by 6:00 AM EST. Thank you for your patience.
A radioimmunoconjugate consisting of a trastuzumab fragment labeled with the positron-emitting radioisotope gallium Ga 68 with radioisotopic and antibody activities. Upon administration, Ga-68-labeled F(ab’)2-trastuzumab may bind to HER2-positive tumor cells, allowing radioimmunolocalization with positron emission tomography (PET). Trastuzumab is a recombinant humanized monoclonal antibody that selectively binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for active clinical trials using this agent. (NCI Thesaurus)